Anti-GARP protein
The present invention relates to a protein binding to GARP in the presence of TGF-β and uses thereof.
1. An anti-human Glycoprotein A repetitions predominant (hGARP) antibody, comprising
a heavy chain variable region comprising the following CDRs:
VH-CDR1:
(SEQ ID NO: 52)
GYGIN;
VH-CDR2:
(SEQ ID NO: 3)
MIWSDGSTDYNSVLTS; and
VH-CDR3:
(SEQ ID NO: 4)
DRNYYDYDGAMDY.
a light chain variable region comprising the following CDRs:
VL-CDR1:
(SEQ ID NO: 5)
KASDHIKNWLA;
VL-CDR2:
(SEQ ID NO: 6)
GATSLEA;
and
VL-CDR3:
(SEQ ID NO: 7)
QQYWSTPWT.
2. An antibody or antigen binding fragment produced by a hybridoma registered under the accession number LMBP 10246CB on May 30, 2013.
3. A hybridoma cell line producing an antibody against GARP registered under the accession number LMBP 10246CB on May 30, 2013.
4. A polynucleotide sequence encoding the antibody molecule of claim 1 .
5. An expression vector comprising the polynucleotide sequence of claim 4 .
6. An isolated host cell comprising the vector of claim 5 .
7. A method of producing an anti-hGARP antibody, comprising culturing the host cell of claim 6 under conditions to express the antibody, and recovering the expressed antibody.
8. The antibody of claim 1 , which is labeled with a detectable label, wherein the detectable label comprises at least one element, isotope, or chemical compound attached to the antibody to enable detection.
9. A kit comprising the antibody of claim 1 , wherein the kit is used to identify the presence of a complex of hGARP and latent TGF-β1 in a biological sample.
10. A kit comprising the antibody of claim 1 , wherein the kit is used to identify activated Tregs in a biological sample.
11. The anti-hGARP antibody of claim 1 , wherein the heavy chain variable region comprises a VH-CDR1 having the amino acid sequence of GFSLTGYGIN (SEQ ID NO:2).
12. The anti-hGARP antibody of claim 1 , wherein the antibody is a humanized antibody.
13. The antibody of claim 12 , which is an IgG1 or IgG4 antibody.
14. The anti-hGARP antibody of claim 11 , comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:50, and a light chain variable region having the amino acid sequence of SEQ ID NO:51.
15. The anti-hGARP antibody of claim 11 , comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:8, and a light chain variable region having the amino acid sequence of SEQ ID NO:9.